<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1027-2852</journal-id>
<journal-title><![CDATA[Biotecnología Aplicada]]></journal-title>
<abbrev-journal-title><![CDATA[Biotecnol Apl]]></abbrev-journal-title>
<issn>1027-2852</issn>
<publisher>
<publisher-name><![CDATA[Editorial Elfos Scientiae]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1027-28522016000300002</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Molecular associations of Primary Open-Angle Glaucoma with potential comorbid diseases (POAG-associome)]]></article-title>
<article-title xml:lang="es"><![CDATA[Asociaciones moleculares del glaucoma primario de ángulo abierto (POAG) con enfermedades comórbidas potenciales (asocioma de POAG)]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Saik]]></surname>
<given-names><![CDATA[Olga V]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Konovalova]]></surname>
<given-names><![CDATA[Natalia A]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Demenkov]]></surname>
<given-names><![CDATA[Pavel S]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ivanisenko]]></surname>
<given-names><![CDATA[Timofey V]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Petrovskiy]]></surname>
<given-names><![CDATA[Evgeny D]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ivanisenko]]></surname>
<given-names><![CDATA[Nikita V]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ivanoshchuk]]></surname>
<given-names><![CDATA[Dinara E]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ponomareva]]></surname>
<given-names><![CDATA[Maria N]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Konovalova]]></surname>
<given-names><![CDATA[Olga S]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lavrik]]></surname>
<given-names><![CDATA[Inna N]]></given-names>
</name>
<xref ref-type="aff" rid="A04"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Kolchanov]]></surname>
<given-names><![CDATA[Nikolay A]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ivanisenko]]></surname>
<given-names><![CDATA[Vladimir A]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A02">
<institution><![CDATA[,Ministry of Healthcare of the Russian Federation Federal State Budgetary Educational Institution of Higher Education &ldquo;Tyumen State Medical University&rdquo; ]]></institution>
<addr-line><![CDATA[Tyumen ]]></addr-line>
<country>Russia</country>
</aff>
<aff id="A03">
<institution><![CDATA[,Novosibirsk State University  ]]></institution>
<addr-line><![CDATA[Novosibirsk ]]></addr-line>
<country>Russia</country>
</aff>
<aff id="A04">
<institution><![CDATA[,Otto von Guericke University Institute of Experimental Internal Medicine Department of Translational Inflammation]]></institution>
<addr-line><![CDATA[Magdeburg ]]></addr-line>
<country>Germany</country>
</aff>
<aff id="A01">
<institution><![CDATA[,The Siberian Branch of the Russian Academy of Sciences The Federal Research Center Institute of Cytology and Genetics ]]></institution>
<addr-line><![CDATA[Novosibirsk ]]></addr-line>
<country>Russia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2016</year>
</pub-date>
<volume>33</volume>
<numero>3</numero>
<fpage>3201</fpage>
<lpage>3206</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1027-28522016000300002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1027-28522016000300002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1027-28522016000300002&amp;lng=en&amp;nrm=iso"></self-uri><kwd-group>
<kwd lng="en"><![CDATA[primary open-angle glaucoma]]></kwd>
<kwd lng="en"><![CDATA[POAG]]></kwd>
<kwd lng="en"><![CDATA[comorbid diseases]]></kwd>
<kwd lng="en"><![CDATA[apoptosis]]></kwd>
<kwd lng="en"><![CDATA[endothelial dysfunction]]></kwd>
<kwd lng="en"><![CDATA[ANDSystem]]></kwd>
<kwd lng="en"><![CDATA[gene networks]]></kwd>
<kwd lng="es"><![CDATA[glaucoma primario de ángulo abierto primario]]></kwd>
<kwd lng="es"><![CDATA[POAG]]></kwd>
<kwd lng="es"><![CDATA[enfermedades comórbidas]]></kwd>
<kwd lng="es"><![CDATA[apoptosis]]></kwd>
<kwd lng="es"><![CDATA[disfunción endotelial]]></kwd>
<kwd lng="es"><![CDATA[ANDSystem]]></kwd>
<kwd lng="es"><![CDATA[redes de genes]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <DIV class="Sect"   >        <P align="right"   ><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"><B>RESEARCH      </b></font></P >   <FONT size="+1" color="#211E1F"><B>        <P   >&nbsp;</P >       <P   ><font size="4" face="Verdana, Arial, Helvetica, sans-serif">Molecular associations      of Primary Open-Angle Glaucoma with potential comorbid diseases (POAG-associome)      </font></P >       <P   ></P >   </B> <FONT size="+1" color="#000000">        <P   >&nbsp;</P >       <P   ><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"><B><font size="3">Asociaciones      moleculares del glaucoma primario de &aacute;ngulo abierto (POAG) con enfermedades      com&oacute;rbidas potenciales (asocioma de POAG) </font></b></font></P >       <P   >&nbsp;</P >       <P   >&nbsp;</P >   <FONT size="+1" color="#211E1F">        <P   > </P >       ]]></body>
<body><![CDATA[<P   ></P >   <FONT size="+1" color="#000000">        <P   ><b><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif">Olga      V Saik<sup>1</sup>, Natalia A Konovalova<sup>2</sup>, Pavel S Demenkov<sup>1</sup>,      Timofey V Ivanisenko<sup>1,3</sup>, Evgeny D Petrovskiy<sup>1</sup>, Nikita      V Ivanisenko<sup>1,3</sup>, Dinara E Ivanoshchuk<sup>1</sup>, Maria N Ponomareva<sup>2</sup>,      Olga S Konovalova<sup>2</sup>, Inna N Lavrik<sup>1,4</sup>, Nikolay A Kolchanov<sup>1</sup>,      Vladimir A Ivanisenko<sup>1</sup> </font></b><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></P >   <FONT size="+1" color="#211E1F"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1">        <P   > </P >   <FONT size="+1" color="#000000">        <P   ><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"><sup>1</sup>      The Federal Research Center Institute of Cytology and Genetics, The Siberian      Branch of the Russian Academy of Sciences. Prospekt Lavrentyeva 10, 630090,      Novosibirsk, Russia. </font>    <br>     <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>2</sup> Federal      State Budgetary Educational Institution of Higher Education &ldquo;Tyumen      State Medical University&rdquo; of the Ministry of Healthcare of the Russian      Federation. Odessa street, 54, 625023, Tyumen, Russia. </font>    <br>     <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>3</sup> Novosibirsk      State University. Pirogova street 2, 630090, Novosibirsk, Russia. </font>    <br>     <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>4</sup> Department      of Translational Inflammation, Institute of Experimental Internal Medicine,      Otto von Guericke University. Leipziger Stra&szlig;e 44, D-39120, Magdeburg,      Germany. </font></P >   <FONT size="+1" color="#211E1F"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1">        <P   >&nbsp;</P >       <P   >&nbsp;</P >   </font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font>    <hr>   <FONT size="+1" color="#211E1F"><FONT size="+1" color="#000000"><FONT size="+1" color="#211E1F"><FONT size="+1" color="#000000"><FONT size="+1" color="#211E1F"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1" color="#000000"><FONT size="+1" color="#211E1F"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1">        <P   ><b><font size="2" face="Verdana, Arial, Helvetica, sans-serif">ABSTRACT </font></b></P >   <FONT size="+1"><FONT size="+1">        ]]></body>
<body><![CDATA[<P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Glaucoma is the leading      cause of irreversible vision loss, which is caused by death of the retinal      ganglion cells. Cur-rently, glaucoma affects over 60 million people worldwide      with primary open-angle glaucoma (POAG) being one of the most common forms      of the disease. Despite the large amount of research devoted to glaucoma,      molecular and genetic mechanisms of its development are still poorly understood.      Thus, the aim of the present study was pre-diction of new potentially comorbid      diseases of POAG, based on analysis of associative gene networks describing      disease-disease interactions. Application of enrichment analysis to associative      networks, constructed with the AND-System for 31 diseases that are comorbid      to POAG according to the literature data, revealed that 10 diseases had a      statistically significant overlap of proteins/genes with the POAG associative      network (p-value &lt; 0.01). Comparison of POAG with over 4000 diseases with      the aid of the ANDSystem showed that there was a statistically significant      overrepresentation of proteins/genes in the POAG associative network for more      than 100 diseases. Analysis of Gene Ontology (GO) biological processes showed      the importance of apoptosis-related and endothelium-related processes for      the formation of comorbid conditions of POAG with cancer and cardiovascular      diseases, among others. </font></P >       <P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b><i>Keywords:</i></b>      primary open-angle glaucoma, POAG, comorbid diseases, apoptosis, endothelial      dysfunction, ANDSystem, gene networks.</font></P >   </font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font>   <hr>   <FONT size="+1" color="#211E1F"><FONT size="+1" color="#000000"><FONT size="+1" color="#211E1F"><FONT size="+1" color="#000000"><FONT size="+1" color="#211E1F"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1" color="#000000"><FONT size="+1" color="#211E1F"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1">        <P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RESUMEN </b></font></P >       <P   > </P >   <FONT size="+1" color="#000000">        <P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> <FONT color="#211E1F">El      glaucoma es la principal causa de la p&eacute;rdida irreversible de la visi&oacute;n,      que ocurre por la muerte de las c&eacute;lulas ganglionares de la retina.      El glaucoma afecta a 60 millones de personas en el mundo y la forma conocida      como glaucoma primario de &aacute;ngulo abierto (POAG) es una de las m&aacute;s      frecuentes. A pesar de los abundantes estudios sobre el glaucoma, aun se comprenden      poco los mecanismos moleculares y gen&eacute;ticos que motivan su desarrollo.      Por tales razones, el prop&oacute;sito de este estudio consisti&oacute; en      predecir cu&aacute;les son las enfermedades que muestran </font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">comorbilidad      con el POAG, mediante el an&aacute;lisis de las redes de asociaci&oacute;n      de genes que describen las interacciones entre enfermedades. Diez enfermedades      mostraron un solapamiento significativo de prote&iacute;nas y genes con la      red asociativa del POAG (p &lt; 0.01). Ello fue posible tras el an&aacute;lisis      de enriquecimiento de redes asociativas, construidas con el empleo del sistema      ANDSystem, a partir de 31 enfermedades para las que se hab&iacute;a descrito      comorbilidad con el POAG en la literatura cient&iacute;fica. La comparaci&oacute;n      del POAG con 4000 enfermedades, con la ayuda del sistema ANDSystem, mostr&oacute;      una representaci&oacute;n incrementada significativa de prote&iacute;nas y      genes en la red asociativa de POAG para m&aacute;s de 100 enfermedades. El      an&aacute;lisis de procesos biol&oacute;gicos en la Ontolog&iacute;a de Genes      (GO) permiti&oacute; determinar la importancia de los procesos vinculados      a la apoptosis y al endotelio, para la formaci&oacute;n de condiciones de      comorbilidad del POAG con el c&aacute;ncer y las enfermedades cardiovasculares,      entre otras. </font></P >   <FONT size="+1"><FONT size="+1" color="#211E1F">        <P   ><font size="2" color="#000000" face="Verdana, Arial, Helvetica, sans-serif"><i><b>Palabras      clave:</b></i> <FONT color="#211E1F">glaucoma primario de &aacute;ngulo abierto      primario, POAG, enfermedades com&oacute;rbidas, apoptosis, disfunci&oacute;n      endotelial, ANDSystem, redes de genes. </font></font></P >   </font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font>   <hr>   <FONT size="+1" color="#211E1F"><FONT size="+1" color="#000000"><FONT size="+1" color="#211E1F"><FONT size="+1" color="#000000"><FONT size="+1" color="#211E1F"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1" color="#000000"><FONT size="+1" color="#211E1F"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1"><FONT size="+1" color="#000000"><FONT size="+1"><FONT size="+1" color="#211E1F"><FONT size="+1" color="#000000"><FONT size="+1" color="#211E1F">        <P   > </P >       <P   > </P >       <P   > </P >       <P   >&nbsp;</P >       ]]></body>
<body><![CDATA[<P   >&nbsp;</P >       <P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b><font size="3">INTRODUCTION      </font></b></font></P >       <P   ><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Glaucoma      is a neurodegenerative disease characterized by the progressive loss of retinal      ganglion cells, followed by a distinctive visual field constriction, and eventually      by loss of vision [1]. In most cases, glaucoma is caused by an increase in      intraocular pressure, although it may also develop under normal eye physiology,      and primary open-angle glaucoma (POAG) is one of the commonest [2]. Therefore,      current therapies for the disease are directed at reducing intraocular pressure;      methods include laser or surgical intervention, and drug exposure. Unfortunately,      these therapies are unable to stop the disease process completely and allow      only to slow down the loss of eye function [1-4].</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">The      presence of comorbid conditions contribute to hinder the diagnosis of many      diseases, and can also lead to a decrease in treatment effectiveness, even      with the correct diagnosis. Comorbidity is defined as the manifestation of      an additional clinical condition that exists or arises in the background of      a present illness [5]. It is a complex combination of several diseases, which      tend to coexist in patients more frequently than it would be expected for      random chance [6]. Thereby, predicting potential comorbid diseases is an urgent      task for modern medicine. Moreover, the analysis of the molecular mechanisms      of comorbid conditions can provide insight on the pathogenesis of the disease      and a basis to search for new therapeutic targets [7].</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Currently,      reconstruction and analysis of molecular genetic networks is a widely used      approach to study the molecular mechanisms of complex biological functioning      and interaction processes, including the formation of pathological conditions      [6-9]. To understand the mechanisms of comorbidity, it is important to identify      the so-called pleiotropic genes, which are simultaneously involved in the      development of several different pathological conditions [7]. Obviously, the      degree of interaction between the molecular genetic networks associated with      different diseases can play an important role in the formation of comorbid      conditions. In particular, Lee <i>et al</i>. [10] showed that genes associated      with comorbid diseases were frequently involved in the same metabolic process.      Previously, using the example of asthma (BA) and tuberculosis (TB), we showed      that the degree of intersection (according to Jaccard and meet/min indexes)      of networks associated with comorbid diseases is significantly higher than      that for the random pairs of diseases [11]. We performed a similar analysis      to Glotov <i>et al</i>., which showed a significantly closer relationship      between pre-eclampsia, diabetes mellitus, gestational diabetes and obesity,      compared with random pairs of diseases [12].</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Therefore,      this work was aimed to study of the interaction between the POAG and 4711      other diseases, by searching for potentially comorbid diseases. To achieve      this goal, we used the ANDSystem and earlier developed techniques of reconstructing      gene networks associated with a disease [13]. Analysis of overrepresentation      of genes from the associative gene network of POAG in the gene networks of      other diseases allowed us to predict 107 potential comorbid diseases with      POAG diseases (p-value &lt; 0.01). Of them, 10 were confirmed in the literature      as having possible comorbidity with glaucoma, and the remaining 97 diseases      can be referred to as new potential comorbid diseases with POAG. Results on      the role of genes involved in endothelium-related GO biological processes      in the POAG associated gene network may serve as evidence in favor of the      assumption that peripheral vascular endothelial dysfunction may be related      to glaucoma progression [15].</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       <P   >&nbsp;</P >       <P   > </P >       <P   ><b><font size="3" face="Verdana, Arial, Helvetica, sans-serif">MATERIALS AND      METHODS</font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></b></P >       <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">To      generate a list of human genes associated with POAG and 4711 other diseases,      a previously developed ANDSystem tool was used, which comprises a knowledge      base of interactions and associations between molecular genetic entities,      as well as diseases, biological processes, and other parameters [13]. It was      created via automatic extraction of information from scientific publications      and factual databases.</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       ]]></body>
<body><![CDATA[<P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">The      Gene Ontology (Gene Ontology Consortium, GO; <FONT color="#0000FF"><a href="http://geneontology.org/" target="_blank">http://geneontology.org/</a><FONT color="#211E1F">)      overrepresentation analysis was performed using the DAVID resource (<FONT color="#0000FF"><a href="https://david-d.ncifcrf.gov/summary.jsp" target="_blank">https://david-d.ncifcrf.gov/summary.jsp</a><FONT color="#211E1F">)      [16]. The </font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">list      of human genes/proteins related to the GO category &laquo;Apoptotic process&raquo;      was created by searching genes for the keyword &laquo;apoptotic process&raquo;.</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >   <FONT color="#0000FF"><FONT color="#211E1F"><FONT color="#0000FF"><FONT color="#211E1F">        <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">The      list of human proteins/genes associated with the endothelium was constructed      in two steps. First, 153 GO biological processes were selected with keywords      &laquo;endothelium&raquo; or &laquo;endothelial&raquo; in the title. Next,      the subset of 403 genes/proteins related to these GO biological processes      and having the GO annotations for human was selected.</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">The      gene networks associated with POAG were reconstructed by using the ANDSystem.      Betweenness centrality for each node of the analyzed associative gene network      was calculated with the <i>igraph</i> package implemented in the R programming      language [17]. Prediction of comorbid diseases of POAG was based on an evaluation      of the statistical significance of overrepresentation of genes associated      with POAG, among the list of genes associated with the disease under analysis.      The statistical significance of genes overrepresentation was calculated by      using the hypergeometric distribution, adjusted for multiple comparisons (FDR      and Bonferroni correction), with the <i>stats.hypergeom. sf</i> function of      the <i>SciPy</i> package implemented in the Python programming language and      the <i>p.adjust</i> function of the stats package implemented in R [18, 19].</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">To      generate a list of comorbid diseases of glaucoma found in the literature,      abstracts containing the keywords &ldquo;glaucoma&rdquo; and &ldquo;comorbidity&rdquo;      were found in PubMed. After manual inspection of the papers retrieved, a list      of diseases explicitly mentioned as being comorbid with respect to glaucoma      was extracted.</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       <P   >&nbsp;</P >       <P   > </P >       <P   ><b><font size="3" face="Verdana, Arial, Helvetica, sans-serif">RESULTS AND DISCUSSION      </font></b></P >       <P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><B>Analysis of the      molecular and genetic mechanisms underlying POAG pathogenesis </b></font></P >       <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">POAG      is one of the basic, most common forms of glaucoma. Glaucoma is characterized      by a persistent increase in intraocular pressure, accompanied by a progressive      loss of retinal ganglion cells. Neverthe-less, ganglion cell death mechanism      still has not been studied in detail, but it was assumed that apoptosis plays      a key role in this process [14]. Unfortunately, modern methods for treating      glaucoma and POAG do not completely stop the disease progression and only      slowdown the loss of eye function [1-4].</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">In      order to search for the molecular and genetic mechanisms underlying the development      of POAG, we formed a list of 96 genes associated with glaucoma modality, according      to the ANDSystem. Analysis of GO biological processes revealed that the most      overrepresented processes (p-value &lt; 0.05) were those related to the extracellular      matrix, immune system, circulatory system, regulation of apoptotic process,      response to hypoxia, response to drug, and others (<a href="/img/revistas/bta/v33n3/t0102316.gif">Table      1</a>).</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       
]]></body>
<body><![CDATA[<P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">It      is known that the extracellular matrix plays an important role in the formation      and functioning of tissues. Violation of the extracellular matrix causes loss      of elasticity and integrity of tissues [20, 21] and may serve as one of the      reasons for dysfunctions in intraocular fluid outflow.</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Another      process, endothelial dysfunction, is studied as one of the potential mechanisms      of POAG [15]. Endothelium lines the walls of blood vessels and plays an important      role in the circulatory system. Particularly, the vascular endothelium is      involved in the maintenance of vascular homeostasis and regulation of vascular      tone [15]. In fact, dysfunction of endothelium is considered an important      factor for development of systemic diseases such as atherosclerosis, hypertension,      heart failure and others [22]. Previous works discuss on the role of vascular      endothelial cell dysfunction in glaucoma patients [23-26]. Our results were      consistent with those evidences since &laquo;blood coagulation&raquo; and      &laquo;angiogenesis&raquo; processes were found among the most overrepresented      GO Biological Processes. Unexpectedly, the categories that are directly related      to the endothelium were not present among the significant GO biological processes.      There were 153 biological processes identified containing the word &bdquo;endothelium&#8223;      in the title. According to the number of genes involved in these processes,      ranging from 1 to 104 (median of 4), they are still poorly investigated. Therefore,      one of the reasons why endothelial processes were not statistically significant      can be their insufficient annotation.</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Connections      between the immune system, apoptosis and glaucoma have been widely discussed      [27- 29]. Recent studies show that glaucoma is not purely degenerative, but      also involves inflammatory and immune elements [27] and could include autoimmune      processes [28, 29].</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Similarly,      apoptosis has been pointed out as significant for the destruction of retinal      ganglion cells in glaucoma [14]. Apoptosis, the programmed cell death regulated      by specific signals, drives cells to undergo organized cellular organelles      degradation by activated proteolytic caspases (Cas). Additionally, apoptosis-inducing      factors can activate Cas-independent apoptotic pathways. Moreover, it is known      that unregulated apoptotic cell death is involved in some neurodegenerative      diseases [30, 31].</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">The      importance of genes for the functioning of certain biological processes may      also be evaluated based on the value of their centrality in the gene networks      describing them [32, 33]. For the analysis of the centrality of genes associated      with POAG, an associative gene network of POAG was reconstructed using the      ANDSystem [13]. The resulting network contained 1289 links of 14 different      types of interac-tions presented in ANDSystem, the most significant being:      expression regulation, activity regulation, transport regulation, co-expression,      protein-protein interactions, among others. The betweenness centrality (BC)      value was calculated for each of the nodes of the network. Noteworthy, the      average centrality of nodes corresponding to proteins (BC = 113.46), was approximately      twice the average centrality for the nodes corresponding to genes (BC = 64.81).      This is primarily due to the fact that there is more data present in the literature      on the intermolecular interactions in which proteins may be involved, compared      to the regulatory interactions of genes. For instance, the p53 protein was      ranked first in the list of genes, which were ordered descending by their      betweenness centrality. At the same time, TP53 gene was located in third place,      which also corresponds to a high degree of node centrality. It is known that      p53 is a hub and plays an important role in many biological processes including      apoptosis, so its high centrality was quite expected.</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Besides      that, genes involved in the GO category &laquo;apoptotic process&raquo;, had      a significantly higher average value of betweenness centrality (174.73) than      the average of all the vertices of the network (88.84), with p-value &lt;      10<sup>-4</sup>. In this connection, apoptosis can be considered one of the      central biological processes in the POAG network. Surprising for us was the      fact that the nodes ranked by highest centrality and following the p53 protein      corresponded to the proteins tumor necrosis factor (TNF), interleukin 6 (IL6),      fibronectin protein (FN1) and caveolin 1 (CAV1), which are involved in the      endothelium-related GO biological process. This is also consistent with the      idea of the role of endothelial dysfunction in the development of POAG.</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >   <FONT size="+1"><FONT size="+1">        <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">A      large number of links present in the POAG gene network made it difficult to      illustrate its comprehensive graphical representation, so we built a subnet,      which included only regulatory connections, for the purpose of network visualization      (<a href="/img/revistas/bta/v33n3/f0102316.gif">Figure 1</a>). Such connections are of particular      interest in the analysis of molecular genetic networks, in spite of their      exclusion by most existing systems.</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       
<P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">As      shown in <a href="/img/revistas/bta/v33n3/f0102316.gif">figure 1</a>, 16 out of the 36 proteins are      involved in the regulation of expression. For instance, the protein IL-6 enhances      the expression of the genes of matrix metallopeptidases 3 and 13 (Mmp3 and      Mmp13, respectively), and TNF-alpha protein induces expression the expression      of the inducible nitric oxide synthase (iNOS) in various cell types. Twenty-four      proteins were involved in the regulation of protein activity, including p21      protein which blocks p53 functions in stem cells; and TNF protein which increases      proapoptotic p53 levels in foetal membranes. Fourteen proteins take part on      the regulation of transport/release, including the Toll-like receptor 4 protein      (TLR4), a pathogen-as-sociated molecular pattern receptor which mediates silica-induced      TNF-alpha release from macrophages [34], and TGF-beta2, which can induce the      sustained release of MMP-2 [35]. It was found that p53 protein participates      in the highest number of different types of regulatory relations, including      associations with two genes (TP53 and the Cyclin Dependent Kinase Inhibitor      1A (CDKN1A)) and eight proteins (p21, plasminogen activator inhibitor-1 (PAI1),      TNF-alpha, MMP2, MMP9, hexokinase 2 (HXK2), neuron specific gene family member      1 (NSG1) and the Transcription elongation factor A protein-like 1 (TCAL1))      with the following types of connections: expression regulation, activity upregulation,      activity regulation, activity downregulation, degradation downregulation,      expression downregulation, and expression.</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       
<P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><B>Prediction of      diseases comorbid to POAG </b></font></P >       <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">In      this study, we revealed potential comorbid diseases of POAG. We suggest that      comorbid diseases are more closely related to each other at the molecular      genetic level and have a higher number of common genes than random pairs of      diseases. It is known that bronchial asthma (BA) and tuberculosis (TB) are      dystrophic diseases [11]. In Bragina<i> et al</i>. [11], using the example      of BA and TB, we have shown that the number of genes in the intersection of      gene networks specific to BA and TB is significantly higher than the number      of genes in the intersections of gene networks of randomly selected pairs      of diseases. This pattern was maintained not only for the absolute number      of genes, but also for the percentage of genes included in the intersection,      relative to the total number of genes of the two networks, which was shown      by Jaccard&#8223;s and meet/min indices.</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       ]]></body>
<body><![CDATA[<P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">An      analysis was performed on the interaction between POAG and 4711 other diseases      by considering the number of common genes to them. The overrepresentation      of genes associated with POAG was further estimated among the list of genes      associated with the analyzed diseases. The statistically significant relationships      between a pair of diseases were defined by assessing the overrepresentation      of genes associated with one disease, among the genes associated with other      diseases of the analyzed pair. This approach was used to determine the connectivity      between POAG and the 4711 diseases, and revealed the diseases significantly      associated with POAG, according to the presence of common genes associated      with both diseases simultaneously. Up to 107 diseases were found for which      the overrepresentation of genes was significant with Bonferroni correction      (p-value &lt; 0.01). Among the most significant diseases (p-value &lt; 10<sup>-9</sup>)      identified were: endometriosis, hepatitis, ovarian neoplasms, diabetic retinopathy,      coronary artery disease and urinary bladder neoplasms.</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >   <FONT size="+1"><FONT size="+1">        <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">In      the next step, we searched for comorbid diseases of glaucoma known in the      literature. Using keywords &ldquo;glaucoma&rdquo; and &ldquo;comorbidity&rdquo;,      a corpus of PubMed abstracts was formed and subjected to manual analysis,      aimed at identifying the list of diseases for which the authors mention their      comorbidity with respect to glaucoma. The literature search revealed 31 such      diseases (<a href="/img/revistas/bta/v33n3/t0202316.gif">Table 2</a>). The results indicated that      10 of the 31 comorbid diseases for glaucoma found in the literature were significantly      overrepresented with a p-value less than 0.01.</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       
<P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><B>Involvement of      apoptosis and endothelium-related GO biological processes in interactions      between POAG and comorbid diseases </b></font></P >       <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">The      literature extensively discusses the contribution of apoptosis and endothelial      dysfunction to glaucoma development [14, 15, 23-26]. Our analysis of overrepresented      biological processes for genes associated with POAG, showed that apoptosis      is among the top of the list of significantly processes. Also, it is known      that, blood coagulation and angiogenesis, which were found in our top list      as well, are related to different endothelial dysfunctions, and disturbances      in apoptosis and endothelial function are important factors in pathogenesis      of many diseases [22, 30, 31]. Therefore, we were interested in analysing      the overrepresentation of genes involved in apoptosis and endothelial dysfunction      among genes associated simultaneously with both POAG and potentially comorbid      diseases.</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       <P   > </P >       <P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">For that purpose,      in the first step, 107 diseases from the ANDSystem were selected which had      statistically significant connection with POAG by associated networks overlap      (p-value &lt; 0.01). We considered such diseases as potentially comorbid to      POAG. Further, for each of the 107 diseases, a list of genes associated with      both POAG and the analyzed diseases was formed, with apoptosis significantly      overrepresented in this list of genes (Bonferroni-corrected p-value &lt; 0.01)      for 18 diseases. They included: cancer (colorectal neoplasms, prostatic neoplasms      and breast neoplasms), cardiovas-cular diseases (cardiovascular diseases,      myocardial infarction, hypertension, heart failure, atherosclerosis), including      those found in the literature as potential comorbid diseases for glaucoma      (hypertension and diabetic retinopathy).</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Regarding      endothelial dysfunction, endothelium-related GO biological processes were      significantly overrepresented in 27 of the 107 diseases (Bonferroni-corrected      p-value &lt; 0.01), among them: cardio-vascular (hypertension, heart failure,      pre-eclampsia, aortic aneurysm, abdominal, myocardial infarction, atherosclerosis),      kidney diseases (glomerulonephritis, renal insufficiency, glomerulonephritis,      membranous, diabetic nephropathies) and cancer (prostatic neoplasms, ovarian      neoplasms, carcinogenesis, pancreatic neoplasms, urinary bladder neoplasms,      breast neoplasms, leukaemia).</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">To      illustrate the interactions between POAG and potential comorbid diseases at      the molecular genetic level, we selected diabetic retinopathy (<a href="/img/revistas/bta/v33n3/f0202316.gif">Figure      2</a>). In the literature, some authors consider diabetic retinopathy as comorbid      in relation to POAG [43]. The associative gene network, reconstructed with      the ANDSystem, describes the interaction between POAG and diabetic retinopathy      for 165 genes and 162 proteins with 5437 interactions. The &ldquo;regulation      of expression&rdquo; interaction type was chosen for a graphical representation      of the network, since it is the best one for the representation of regulatory      crosstalk between networks. The network is divided into three parts: the left      side corresponds to the genes/proteins associated only with diabetic retinopathy,      the central part corresponds to the genes/proteins associated with both diabetic      retinopathy and POAG, and the right side is associated only with POAG. As      shown in <a href="/img/revistas/bta/v33n3/f0202316.gif">figure 2</a>, the regulatory interactions      between genes associated with diabetic retinopathy and genes associated with      POAG mainly pass through the central part of the network. In other words,      genes simultaneously associated with both diseases can act as an interface      in the interactions between gene networks for these diseases. This can be      one of the reasons why comorbid diseases have common genes.</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></P >       
<P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Particularly,      it was found that the genes/proteins involved in apoptosis are distributed      in approximately equal proportions among all three parts of the POAG/diabetic      retinopathy regulatory network (<a href="/img/revistas/bta/v33n3/f0202316.gif">Figure 2</a>): 0.61,      0.72 and 0.7, respectively. It should be noted that apoptosis plays an important      role in the development of both diabetic retinopathy [49, 50] and POAG [14].</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       
<P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">In      summary, an analysis of associative gene networks allowed us to predict 97      new potentially co-morbid diseases of POAG. These data emphasise the roles      of apoptosis and endothelial dysfunction in POAG comorbidity to other diseases.</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       ]]></body>
<body><![CDATA[<P   >&nbsp;</P >       <P   > </P >       <P   ><font size="3"><b><font face="Verdana, Arial, Helvetica, sans-serif">ACKNOWLEDGEMENTS      </font></b></font></P >       <P   ><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Reconstruction      and analysis of the associative gene networks related to apoptosis, and identification      of key genes in these networks were supported by the Russian Science Foundation      grant &ldquo;Programmed cell death induced via death receptors: Delineating      molecular mechanisms of apoptosis initiation via molecular modeling&rdquo;      14-44-00011. Development of the method for analysis of interactions between      associative gene networks, based on their overlap, and their application to      the analysis of POAG was performed with the support of the Russian Science      Foundation grant No 14-24-00123 &ldquo;Computer systems biology: analysis      and modelling of structural and functional organization and evolution of genetic      networks&rdquo;.</font><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1"><font size="+1" color="#000000"><font size="+1"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">      </font></P >       <P   >&nbsp;</P >       <P   > </P >       <P   ><b><font size="3" face="Verdana, Arial, Helvetica, sans-serif">REFERENCES </font></b></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Jindal V. Glaucoma:      an extension of various chronic neurodegenerative disorders. Mol Neurobiol.      2013;48(1):186-9.     </font></P >   <FONT size="+1">        <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Quigley HA. Glaucoma.      Lancet. 2011;377(9774):1367-77.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Almasieh M, Wilson      AM, Morquette B, Cueva Vargas JL, Di Polo A. The molecular basis of retinal      ganglion cell death in glaucoma. Prog Retin Eye Res. 2012;31(2):152-81.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Quigley HA. Neuronal      death in glaucoma. Prog Retin Eye Res. 1999;18(1):39-57.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Feinstein AR.      The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic      Dis. 1970;23(7):455-68.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Puzyrev VP. Genetic      bases of human comorbidity. Genetika. 2015;51(4):491-502.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Zheng W, Rao S.      Knowledge-based analysis of genetic associations of rheumatoid arthritis to      inform studies searching for pleiotropic genes: a literature review and network      analysis. Arthritis Res Ther. 2015;17:202.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Podkolodnaya OA,      Yarkova EE, Demenkov PS, Konovalova OS, Ivanisenko VA, Kolchanov NA. Application      of the ANDCell computer system to reconstruction and analysis of associative      networks describing potential relationships between myopia and glaucoma. Russ      J Gen Appl Res. 2011;1(1):21-8.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Piro RM. Network      medicine: linking disorders. Hum Genet. 2012;131(12):1811-20.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Lee DS, Park      J, Kay KA, Christakis NA, Oltvai ZN, Barabasi AL. The implications of human      metabolic network topology for disease comorbidity. Proc Natl Acad Sci USA.      2008;105(29):9880-5.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Bragina EY, Tiys      ES, Freidin MB, Koneva LA, Demenkov PS, Ivanisenko VA, <i>et al</i>. Insights      into pathophysiology of dystropy through the analysis of gene networks: an      example of bronchial asthma and tuberculosis. Immunogenetics. 2014;66(7-8):457-65.          </font></P >       <P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Glotov AS, Tiys      ES, Vashukova ES, Pakin VS, Demenkov PS, Saik OV, <i>et al</i>. Molecular      association of pathogenetic contributors to pre-eclampsia (pre-eclampsia associome).      BMC Syst Biol. 2015;9 Suppl 2:S4. </font></P >       ]]></body>
<body><![CDATA[<P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Ivanisenko VA,      Saik OV, Ivanisenko NV, Tiys ES, Ivanisenko TV, Demenkov PS, <i>et al</i>.      ANDSystem: an Associative Network Discovery System for automated literature      mining in the field of biology. BMC Syst Biol. 2015;9 Suppl 2:S2. </font></P >       <P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Wang Y, Huang      C, Zhang H, Wu R. Autophagy in glaucoma: Crosstalk with apoptosis and its      implications. Brain Res Bull. 2015;117:1-9. </font></P >       <P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Liu CH, Su WW,      Shie SS, Cheng ST, Su CW, Ho WJ. Association between peripheral vascular endothelial      function and progression of open-angle glaucoma. Medicine (Baltimore). 2016;95(10):e3055.      </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Huang da W, Sherman      BT, Lempicki RA. Systematic and integrative analysis of large gene lists using      DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Csardi G, Nepusz      T. The igraph software package for complex network research. InterJournal,      Complex Systems. 2006;1695(5):1-9.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Johnson NL, Kemp      AW, Kotz S. Univariate discrete distributions. New York: John Wiley &amp;      Sons; 2005.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Benjamini Y,      Hochberg Y. Controlling the false discovery rate: a practical and powerful      approach to multiple testing. J Roy Stat Soc. Series B. 1995:289-300.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Mayazur Rahman      S, Reichenbach A, Zink M, Mayr SG. Mechanical spectroscopy of retina explants      at the protein level employing nanostructured scaffolds. Soft Matter. 2016;12(14):3431-41.          </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Muiznieks LD,      Miao M, Sitarz EE, Keeley FW. Contribution of domain 30 of tropoelastin to      elastic fiber formation and material elasticity. Biopolymers. 2016;105(5):267-75.          </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Verma S, Buchanan      MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease.      Circulation. 2003;108(17):2054-9.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Henry E, Newby      DE, Webb DJ, O&#8223;Brien C. Peripheral endothelial dysfunction in normal      pressure glaucoma. Invest Ophthalmol Vis Sci. 1999;40(8):1710-4.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Buckley C, Hadoke      PW, Henry E, O&#8223;Brien C. Systemic vascular endothelial cell dysfunction      in normal pressure glaucoma. Br J Ophthalmol. 2002;86(2):227-32.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Resch H, Garhofer      G, Fuchsjager-Mayrl G, Hommer A, Schmetterer L. Endothelial dysfunction in      glaucoma. Acta Ophthalmol. 2009;87(1):4-12.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Su WW, Cheng      ST, Ho WJ, Tsay PK, Wu SC, Chang SH. Glaucoma is associated with peripheral      vascular endothelial dysfunction. Ophthalmology. 2008;115(7):1173-8 e1.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Nussenblatt RB,      Liu B, Wei L, Sen HN. The immunological basis of degenerative diseases of      the eye. Int Rev Immunol. 2013;32(1):97-112.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Perez VL, Caspi      RR. Immune mechanisms in inflammatory and degenerative eye disease. Trends      Immunol. 2015;36(6):354-63.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Kamat SS, Gregory      MS, Pasquale LR. The role of the immune system in glaucoma: bridging the divide      between immune mechanisms in experimental glaucoma and the human disease.      Semin Ophthalmol. 2016;31(1-2):147-54.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Taylor RC, Cullen      SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat      Rev Mol Cell Biol. 2008;9(3):231-41.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Pinazo-Duran      MD, Zanon-Moreno V, Garcia-Medina JJ, Gallego-Pinazo R. Evaluation of presumptive      biomarkers of oxidative stress, immune response and apoptosis in primary open-angle      glaucoma. Curr Opin Pharmacol. 2013;13(1):98-107.     </font></P >       <P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Yu H, Kim PM,      Sprecher E, Trifonov V, Gerstein M. The importance of bottlenecks in protein      networks: correlation with gene essentiality and expression dynamics. PLoS      Comput Biol. 2007;3(4):e59. </font></P >       <P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Ozgur A, Vu T,      Erkan G, Radev DR. Identifying gene-disease associations using centrality      on a literature mined gene-interaction network. Bioinformatics. 2008;24(13):i277-85.      </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Yan Z, Zhang      Q, Xu L, Wu WD, Ren WJ, Liu LH, <i>et al</i>. Involvement of Toll-like receptor      in silica-induced tumor necrosis factor alpha release from human macrophage      cell line. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2010;28(6):427-9.          </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Wormstone IM,      Tamiya S, Anderson I, Duncan G. TGF-beta2-induced matrix modification and      cell transdifferentiation in the human lens capsular bag. Invest Ophthalmol      Vis Sci. 2002;43(7):2301-8.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Agorastos A,      Skevas C, Matthaei M, Otte C, Klemm M, Richard G, <i>et al</i>. Depression,      anxiety, and disturbed sleep in glaucoma. J Neuropsychiatry Clin Neurosci.      2013;25(3):205-13.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Lin HC, Chien      CW, Hu CC, Ho JD. Comparison of comorbid conditions between open-angle glaucoma      patients and a control cohort: a case-control study. Ophthalmology. 2010;117(11):2088-95.          </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Shah M, Law G,      Ahmed II. Glaucoma and cataract surgery: two roads merging into one. Curr      Opin Ophthalmol. 2016;27(1):51-7.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">39. Chung SD, Ho      JD, Chen CH, Lin HC, Tsai MC, Sheu JJ. Dementia is associated with open-angle      glaucoma: a population-based study. Eye (Lond). 2015;29(10):1340-6.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">40. Nakamura M, Kanamori      A, Negi A. Diabetes mellitus as a risk factor for glaucomatous optic neuropathy.      Ophthalmologica. 2005;219(1):1-10.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">41. Newman-Casey      PA, Talwar N, Nan B, Musch DC, Stein JD. The relationship between components      of metabolic syndrome and open-angle glaucoma. Ophthalmology. 2011;118(7):1318-26.          </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">42. Tumosa N. Eye      disease and the older diabetic. Clin Geriatr Med. 2008;24(3): 515-27, vii.          </font></P >       <P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">43. Griffith JF,      Goldberg JL. Prevalence of comorbid retinal disease in patients with glaucoma      at an academic medical center. Clin Ophthalmol. 2015;9:1275-84. </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">44. Zidverc-Trajkovic      JJ, Pekmezovic TD, Sundic AL, Radojicic AP, Sternic NM. Comorbidities in cluster      headache and migraine. Acta Neurol Belg. 2011;111(1):50-5.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">45. Lin HC, Kang      JH, Jiang YD, Ho JD. Hypothyroidism and the risk of developing open-angle      glaucoma: a five-year population-based follow-up study. Ophthalmology. 2010;117(10):1960-6.          </font></P >       ]]></body>
<body><![CDATA[<!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">46. Zlateva GP, Javitt      JC, Shah SN, Zhou Z, Murphy JG. Comparison of comorbid conditions between      neovascular age-related macular degeneration patients and a control cohort      in the medicare population. Retina. 2007;27(9):1292-9.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">47. Foster PJ, Jiang      Y. Epidemiology of myopia. Eye (Lond). 2014;28(2):202-8.     </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">48. Ho JD, Hu CC,      Lin HC. Open-angle glaucoma and the risk of stroke development: a 5-year population-based      follow-up study. Stroke. 2009;40(8):2685-90.     </font></P >       <P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">49. Safi SZ, Qvist      R, Kumar S, Batumalaie K, Ismail IS. Molecular mechanisms of diabetic retinopathy,      general preventive strategies, and novel therapeutic targets. Biomed Res Int.      2014;2014:801269. </font></P >       <!-- ref --><P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">50. Adamiec-Mroczek      J, Zajac-Pytrus H, Misiuk-Hojlo M. Caspase-dependent apoptosis of retinal      ganglion cells during the development of diabetic retinopathy. Adv Clin Exp      Med. 2015;24(3):531-5.     </font></P >       <P   >&nbsp;</P >       ]]></body>
<body><![CDATA[<P   >&nbsp;</P >       <P   > </P >       <P   ><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Received in October,      2016.     <br>     </font><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Accepted      in December, 2016. </font></P >       <P   >&nbsp;</P >       <P   >&nbsp;</P >   <FONT size="+1"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="+1" color="#211E1F"><font size="+1" color="#000000"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif"><i>Olga    V Saik</i>. The </font><font size="+1" color="#211E1F"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1"><font size="+1" color="#000000"><font size="2" color="#211E1F" face="Verdana, Arial, Helvetica, sans-serif">Federal    Research Center Institute of Cytology and Genetics, The Siberian Branch of the    Russian Academy of Sciences. Prospekt Lavrentyeva 10, 630090, Novosibirsk, Russia.    E-mail: <a href="mailto:%20saik@bionet.nsc.ru">saik@bionet.nsc.ru</a>. </font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></DIV >      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jindal]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Glaucoma: an extension of various chronic neurodegenerative disorders]]></article-title>
<source><![CDATA[Mol Neurobiol]]></source>
<year>2013</year>
<volume>48</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>186-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quigley]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Glaucoma]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2011</year>
<volume>377</volume>
<numero>9774</numero>
<issue>9774</issue>
<page-range>1367-77</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Almasieh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Morquette]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Cueva Vargas]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Di Polo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The molecular basis of retinal ganglion cell death in glaucoma]]></article-title>
<source><![CDATA[Prog Retin Eye Res]]></source>
<year>2012</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>152-81</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quigley]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Neuronal death in glaucoma]]></article-title>
<source><![CDATA[Prog Retin Eye Res]]></source>
<year>1999</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>39-57</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feinstein]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The pre-therapeutic classification of co-morbidity in chronic disease]]></article-title>
<source><![CDATA[J Chronic Dis]]></source>
<year>1970</year>
<volume>23</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>455-68</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Puzyrev]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Genetic bases of human comorbidity]]></article-title>
<source><![CDATA[Genetika]]></source>
<year>2015</year>
<volume>51</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>491-502</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Knowledge-based analysis of genetic associations of rheumatoid arthritis to inform studies searching for pleiotropic genes: a literature review and network analysis]]></article-title>
<source><![CDATA[Arthritis Res Ther]]></source>
<year>2015</year>
<volume>17</volume>
<page-range>202</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Podkolodnaya]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
<name>
<surname><![CDATA[Yarkova]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Demenkov]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Konovalova]]></surname>
<given-names><![CDATA[OS]]></given-names>
</name>
<name>
<surname><![CDATA[Ivanisenko]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Kolchanov]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Application of the ANDCell computer system to reconstruction and analysis of associative networks describing potential relationships between myopia and glaucoma]]></article-title>
<source><![CDATA[Russ J Gen Appl Res]]></source>
<year>2011</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>21-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piro]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Network medicine: linking disorders]]></article-title>
<source><![CDATA[Hum Genet]]></source>
<year>2012</year>
<volume>131</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1811-20</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kay]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Christakis]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Oltvai]]></surname>
<given-names><![CDATA[ZN]]></given-names>
</name>
<name>
<surname><![CDATA[Barabasi]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The implications of human metabolic network topology for disease comorbidity]]></article-title>
<source><![CDATA[Proc Natl Acad Sci USA]]></source>
<year>2008</year>
<volume>105</volume>
<numero>29</numero>
<issue>29</issue>
<page-range>9880-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bragina]]></surname>
<given-names><![CDATA[EY]]></given-names>
</name>
<name>
<surname><![CDATA[Tiys]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Freidin]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Koneva]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Demenkov]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Ivanisenko]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Insights into pathophysiology of dystropy through the analysis of gene networks: an example of bronchial asthma and tuberculosis]]></article-title>
<source><![CDATA[Immunogenetics]]></source>
<year>2014</year>
<volume>66</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>8):457-65</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glotov]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Tiys]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Vashukova]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Pakin]]></surname>
<given-names><![CDATA[VS]]></given-names>
</name>
<name>
<surname><![CDATA[Demenkov]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Saik]]></surname>
<given-names><![CDATA[OV]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Molecular association of pathogenetic contributors to pre-eclampsia (pre-eclampsia associome)]]></article-title>
<source><![CDATA[BMC Syst Biol]]></source>
<year>2015</year>
<volume>9</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>4</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ivanisenko]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Saik]]></surname>
<given-names><![CDATA[OV]]></given-names>
</name>
<name>
<surname><![CDATA[Ivanisenko]]></surname>
<given-names><![CDATA[NV]]></given-names>
</name>
<name>
<surname><![CDATA[Tiys]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Ivanisenko]]></surname>
<given-names><![CDATA[TV]]></given-names>
</name>
<name>
<surname><![CDATA[Demenkov]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[ANDSystem: an Associative Network Discovery System for automated literature mining in the field of biology]]></article-title>
<source><![CDATA[BMC Syst Biol]]></source>
<year>2015</year>
<volume>9</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>2</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Autophagy in glaucoma: Crosstalk with apoptosis and its implications]]></article-title>
<source><![CDATA[Brain Res Bull]]></source>
<year>2015</year>
<volume>117</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
<name>
<surname><![CDATA[Shie]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Association between peripheral vascular endothelial function and progression of open-angle glaucoma]]></article-title>
<source><![CDATA[Medicine (Baltimore)]]></source>
<year>2016</year>
<volume>95</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>3055</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huang da]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Sherman]]></surname>
<given-names><![CDATA[BT]]></given-names>
</name>
<name>
<surname><![CDATA[Lempicki]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources]]></article-title>
<source><![CDATA[Nat Protoc]]></source>
<year>2009</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>44-57</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Csardi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nepusz]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The igraph software package for complex network research]]></article-title>
<source><![CDATA[InterJournal, Complex Systems]]></source>
<year>2006</year>
<volume>1695</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Kemp]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Kotz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Univariate discrete distributions]]></source>
<year>2005</year>
<publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[John Wiley & Sons]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benjamini]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hochberg]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Controlling the false discovery rate: a practical and powerful approach to multiple testing]]></article-title>
<source><![CDATA[J Roy Stat Soc. Series B]]></source>
<year>1995</year>
<page-range>289-300</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mayazur Rahman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Reichenbach]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zink]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mayr]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mechanical spectroscopy of retina explants at the protein level employing nanostructured scaffolds]]></article-title>
<source><![CDATA[Soft Matter]]></source>
<year>2016</year>
<volume>12</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>3431-41</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muiznieks]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Miao]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sitarz]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Keeley]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Contribution of domain 30 of tropoelastin to elastic fiber formation and material elasticity]]></article-title>
<source><![CDATA[Biopolymers]]></source>
<year>2016</year>
<volume>105</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>267-75</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Buchanan]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Endothelial function testing as a biomarker of vascular disease]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2003</year>
<volume>108</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>2054-9</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Newby]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Webb]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[O·Brien]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Peripheral endothelial dysfunction in normal pressure glaucoma]]></article-title>
<source><![CDATA[Invest Ophthalmol Vis Sci]]></source>
<year>1999</year>
<volume>40</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1710-4</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buckley]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hadoke]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[O·Brien]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Systemic vascular endothelial cell dysfunction in normal pressure glaucoma]]></article-title>
<source><![CDATA[Br J Ophthalmol]]></source>
<year>2002</year>
<volume>86</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>227-32</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Resch]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Garhofer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fuchsjager-Mayrl]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hommer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schmetterer]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Endothelial dysfunction in glaucoma]]></article-title>
<source><![CDATA[Acta Ophthalmol]]></source>
<year>2009</year>
<volume>87</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-12</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tsay]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Glaucoma is associated with peripheral vascular endothelial dysfunction]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2008</year>
<volume>115</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1173-8 e1</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nussenblatt]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sen]]></surname>
<given-names><![CDATA[HN]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The immunological basis of degenerative diseases of the eye]]></article-title>
<source><![CDATA[Int Rev Immunol]]></source>
<year>2013</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>97-112</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
<name>
<surname><![CDATA[Caspi]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Immune mechanisms in inflammatory and degenerative eye disease]]></article-title>
<source><![CDATA[Trends Immunol]]></source>
<year>2015</year>
<volume>36</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>354-63</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kamat]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Gregory]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Pasquale]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The role of the immune system in glaucoma: bridging the divide between immune mechanisms in experimental glaucoma and the human disease]]></article-title>
<source><![CDATA[Semin Ophthalmol]]></source>
<year>2016</year>
<volume>31</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>2):147-54</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Cullen]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Apoptosis: controlled demolition at the cellular level]]></article-title>
<source><![CDATA[Nat Rev Mol Cell Biol]]></source>
<year>2008</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>231-41</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinazo-Duran]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Zanon-Moreno]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Medina]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gallego-Pinazo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Evaluation of presumptive biomarkers of oxidative stress, immune response and apoptosis in primary open-angle glaucoma]]></article-title>
<source><![CDATA[Curr Opin Pharmacol]]></source>
<year>2013</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>98-107</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Sprecher]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Trifonov]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gerstein]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics]]></article-title>
<source><![CDATA[PLoS Comput Biol]]></source>
<year>2007</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>59</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ozgur]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Erkan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Radev]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Identifying gene-disease associations using centrality on a literature mined gene-interaction network]]></article-title>
<source><![CDATA[Bioinformatics]]></source>
<year>2008</year>
<volume>24</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>277-85</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
<name>
<surname><![CDATA[Ren]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Involvement of Toll-like receptor in silica-induced tumor necrosis factor alpha release from human macrophage cell line]]></article-title>
<source><![CDATA[Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi]]></source>
<year>2010</year>
<volume>28</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>427-9</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wormstone]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Tamiya]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Duncan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[TGF-beta2-induced matrix modification and cell transdifferentiation in the human lens capsular bag]]></article-title>
<source><![CDATA[Invest Ophthalmol Vis Sci]]></source>
<year>2002</year>
<volume>43</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2301-8</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Agorastos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Skevas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Matthaei]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Otte]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Klemm]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Richard]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Depression, anxiety, and disturbed sleep in glaucoma]]></article-title>
<source><![CDATA[J Neuropsychiatry Clin Neurosci]]></source>
<year>2013</year>
<volume>25</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>205-13</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Chien]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comparison of comorbid conditions between open-angle glaucoma patients and a control cohort: a case-control study]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2010</year>
<volume>117</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2088-95</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Law]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[II]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Glaucoma and cataract surgery: two roads merging into one]]></article-title>
<source><![CDATA[Curr Opin Ophthalmol]]></source>
<year>2016</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>51-7</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Tsai]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Sheu]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Dementia is associated with open-angle glaucoma: a population-based study]]></article-title>
<source><![CDATA[Eye (Lond)]]></source>
<year>2015</year>
<volume>29</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1340-6</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nakamura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kanamori]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Negi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Diabetes mellitus as a risk factor for glaucomatous optic neuropathy]]></article-title>
<source><![CDATA[Ophthalmologica]]></source>
<year>2005</year>
<volume>219</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Newman-Casey]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Talwar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Nan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Musch]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Stein]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The relationship between components of metabolic syndrome and open-angle glaucoma]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2011</year>
<volume>118</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1318-26</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tumosa]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Eye disease and the older diabetic]]></article-title>
<source><![CDATA[Clin Geriatr Med]]></source>
<year>2008</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>515-27, vii</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Griffith]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Goldberg]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence of comorbid retinal disease in patients with glaucoma at an academic medical center]]></article-title>
<source><![CDATA[Clin Ophthalmol]]></source>
<year>2015</year>
<volume>9</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>1275-84</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zidverc-Trajkovic]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pekmezovic]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Sundic]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Radojicic]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Sternic]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comorbidities in cluster headache and migraine]]></article-title>
<source><![CDATA[Acta Neurol Belg]]></source>
<year>2011</year>
<volume>111</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>50-5</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[YD]]></given-names>
</name>
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hypothyroidism and the risk of developing open-angle glaucoma: a five-year population-based follow-up study]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2010</year>
<volume>117</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1960-6</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zlateva]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Javitt]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comparison of comorbid conditions between neovascular age-related macular degeneration patients and a control cohort in the medicare population]]></article-title>
<source><![CDATA[Retina]]></source>
<year>2007</year>
<volume>27</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1292-9</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Epidemiology of myopia]]></article-title>
<source><![CDATA[Eye (Lond)]]></source>
<year>2014</year>
<volume>28</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>202-8</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Open-angle glaucoma and the risk of stroke development: a 5-year population-based follow-up study]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2009</year>
<volume>40</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2685-90</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Safi]]></surname>
<given-names><![CDATA[SZ]]></given-names>
</name>
<name>
<surname><![CDATA[Qvist]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Batumalaie]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ismail]]></surname>
<given-names><![CDATA[IS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets]]></article-title>
<source><![CDATA[Biomed Res Int]]></source>
<year>2014</year>
<volume>2014</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>801269</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adamiec-Mroczek]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zajac-Pytrus]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Misiuk-Hojlo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Caspase-dependent apoptosis of retinal ganglion cells during the development of diabetic retinopathy]]></article-title>
<source><![CDATA[Adv Clin Exp Med]]></source>
<year>2015</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>531-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
